Pascal CHRISTORY, CEO, AXA IM PRIME joined us at #IPEMCANNES2024 TV Studio for an interview. Watch it, comment it & share it, and stay tuned for the next ones. Sponsored by: IPEM Cannes 2024 TV Studio InterviewsBecome part of the IPEM CommunityWe help foster and engage the Private Capital community internationally through our live and…
It has been reported by the Times that Ireland’s Chanelle Pharma is being vetted ahead of a potential acquisition by UK private equity group, Exponent. Based in Galway, the generic drugmaker is being valued at a deal price of around EUR300 million. It is believed that HIG and Duke Capital were also ‘farming’ to do a deal with the pharmaceutical company, which Michael Burke established four decades ago. Over the years it has built a stable of veterinary licenses for some 3,000 animal medicines across the EU. Exponent will be hoping this deal is just the medicine, as deal activity for the industry at large looks to pick up in 2023. Watch ahead as the Emerald Isle looks set to deliver a gem in Q1.